Explore
Validate
Learn
Western blotAntibody data
- Antibody Data
- Antigen structure
- References [7]
- Comments [0]
- Validations
- Western blot [2]
- Immunohistochemistry [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- MA5-12589 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- Cdc7 Monoclonal Antibody (DCS-341)
- Antibody type
- Monoclonal
- Antigen
- Other
- Description
- MA5-12589 targets CDC7 Kinase in IHC (P), IP, and WB applications and shows reactivity with Human samples.
- Antibody clone number
- DCS-341
- Concentration
- 0.2 mg/mL
Submitted references Increased Cdc7 expression is a marker of oral squamous cell carcinoma and overexpression of Cdc7 contributes to the resistance to DNA-damaging agents.
Dbf4 is direct downstream target of ataxia telangiectasia mutated (ATM) and ataxia telangiectasia and Rad3-related (ATR) protein to regulate intra-S-phase checkpoint.
Geminin overexpression prevents the completion of topoisomerase IIα chromosome decatenation, leading to aneuploidy in human mammary epithelial cells.
Transcriptional co-activator LEDGF interacts with Cdc7-activator of S-phase kinase (ASK) and stimulates its enzymatic activity.
Inhibition of Cdc7/Dbf4 kinase activity affects specific phosphorylation sites on MCM2 in cancer cells.
Geminin is bound to chromatin in G2/M phase to promote proper cytokinesis.
Identification of Mcm2 phosphorylation sites by S-phase-regulating kinases.
Cheng AN, Jiang SS, Fan CC, Lo YK, Kuo CY, Chen CH, Liu YL, Lee CC, Chen WS, Huang TS, Wang TY, Lee AY
Cancer letters 2013 Sep 1;337(2):218-25
Cancer letters 2013 Sep 1;337(2):218-25
Dbf4 is direct downstream target of ataxia telangiectasia mutated (ATM) and ataxia telangiectasia and Rad3-related (ATR) protein to regulate intra-S-phase checkpoint.
Lee AY, Chiba T, Truong LN, Cheng AN, Do J, Cho MJ, Chen L, Wu X
The Journal of biological chemistry 2012 Jan 20;287(4):2531-43
The Journal of biological chemistry 2012 Jan 20;287(4):2531-43
Geminin overexpression prevents the completion of topoisomerase IIα chromosome decatenation, leading to aneuploidy in human mammary epithelial cells.
Gardner L, Malik R, Shimizu Y, Mullins N, ElShamy WM
Breast cancer research : BCR 2011 May 19;13(3):R53
Breast cancer research : BCR 2011 May 19;13(3):R53
Transcriptional co-activator LEDGF interacts with Cdc7-activator of S-phase kinase (ASK) and stimulates its enzymatic activity.
Hughes S, Jenkins V, Dar MJ, Engelman A, Cherepanov P
The Journal of biological chemistry 2010 Jan 1;285(1):541-54
The Journal of biological chemistry 2010 Jan 1;285(1):541-54
Inhibition of Cdc7/Dbf4 kinase activity affects specific phosphorylation sites on MCM2 in cancer cells.
Charych DH, Coyne M, Yabannavar A, Narberes J, Chow S, Wallroth M, Shafer C, Walter AO
Journal of cellular biochemistry 2008 Jun 1;104(3):1075-86
Journal of cellular biochemistry 2008 Jun 1;104(3):1075-86
Geminin is bound to chromatin in G2/M phase to promote proper cytokinesis.
Nakuci E, Xu M, Pujana MA, Valls J, Elshamy WM
The international journal of biochemistry & cell biology 2006;38(7):1207-20
The international journal of biochemistry & cell biology 2006;38(7):1207-20
Identification of Mcm2 phosphorylation sites by S-phase-regulating kinases.
Montagnoli A, Valsasina B, Brotherton D, Troiani S, Rainoldi S, Tenca P, Molinari A, Santocanale C
The Journal of biological chemistry 2006 Apr 14;281(15):10281-90
The Journal of biological chemistry 2006 Apr 14;281(15):10281-90
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Western blot analysis was performed on whole cell extracts (30 µg lysate) of Jurkat (Lane 1), MCF-7 (Lane 2), A-431 (Lane 3), NIH/3T3 (Lane 4),RAW 264.7 (Lane 5), U-2 OS (Lane 6) and Raji (Lane 7). The blots were probed with Mouse Anti-Cdc7 Monoclonal Antibody (Product # MA5-12589, 1 µg/mL) and detected by chemiluminescence using Goat anti-Mouse IgG (H+L) Superclonal™ Secondary Antibody, HRP conjugate (Product # A28177, 0.25 µg/mL, 1:4000 dilution). A 63 kDa corresponding to Cdc7 was observed across the cell lines tested. Known quantity of protein samples were electrophoresed using Novex® NuPAGE® 4-12 % Bis-Tris gel (Product # NP0322BOX), XCell SureLock™ Electrophoresis System (Product # EI0002) and Novex® Sharp Pre-Stained Protein Standard (Product # LC5800). Resolved proteins were then transferred onto a nitrocellulose membrane with iBlot® 2 Dry Blotting System (Product # IB21001). The membrane was probed with the relevant primary and secondary antibody following blocking with 5 % skimmed milk. Chemiluminescent detection was performed using Pierce™ ECL Western Blotting Substrate (Product # 32106).
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Knockdown of Cdc7 was achieved by transfecting MCF7 cells with Cdc7 specific siRNAs (Silencer® select Product # s15827). Western blot analysis (Fig a) was performed using Modified whole cell extract from the Cdc7 knock down cells (lane 1), non-specific scrambled siRNA transfected cells (lane 3) and untransfected cells (lane 2). The blots were probed with Anti-Cdc7 Mouse Monoclonal Antibody (Product # MA5-12589, 0.2 µg/mL) and Goat anti-Mouse IgG (H+L) Superclonal™ Secondary Antibody, HRP conjugate (Product # A28177, 0.25 µg/mL, 1:4000 dilution). Densitometric analysis of this western blot is shown in histogram (Fig b). Loss of signal upon siRNA mediated knock down confirms that antibody is specific to Cdc7.
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Formalin-fixed, paraffin-embedded human tonsil stained with CDC 7 antibody using UltraVision LP kit and AEC chromogen. Note nuclear staining of lymphocytes.
